EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

SUMF1 Common Variant rs793391 Is Associated with Response to Inhaled Corticosteroids in Patients with COPD

Charikleia Ntenti iD, Eleni Papakonstantinou, Leticia Grize, Maria Pascarella iD, Björn C Frye iD, Sebastian Fähndrich iD, Despoina Ioannidou, Spasenija Savic Prince, Antonis Goulas, Daiana Stolz

International Journal of Molecular Sciences · 21.10.2025 · 26 (20) · 10225

DOI: 10.3390/ijms262010225 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.10.2025. Verfasst von Charikleia Ntenti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Respiratory Medicine, University of Freiburg, Faculty of Medicine, University of Freiburg, 79098 Freiburg im Breisgau, Germany. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Polymorphism, Single Nucleotide, Adrenal Cortex Hormones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Foundation, AstraZeneca, Clinic of Pneumology, University Hospital Basel, Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigated whether specific sulfatase modifying factor-1 (SUMF1) SNPs—previously linked to lung function—are associated with COPD progression and response to inhaled corticosteroid (ICS) treatment, specifically budesonide, given that SUMF1 expression is altered in COPD and its variants linked to increased disease risk. A subgroup of 165 COPD patients from the HISTORIC study were genotyped for two common SUMF1 SNPs, rs11915920 and rs793391. Patients first underwent a six-week run-in phase with open-label triple inhaled therapy (LAMA/LABA/ICS), then were randomized to receive either LAMA/LABA/placebo or LAMA/LABA/ICS for 12 months. Associations between SNPs, baseline characteristics, and response to ICS—based on FEV1 change over 12 months—were evaluated. Heterozygotes (TG) for the rs793391 polymorphism treated with LAMA/LABA/ICS showed a significant and clinically meaningful FEV1 improvement compared to the placebo group. This was supported by improved patient-reported outcomes, with lower SGRQ and CAT scores and a clinically relevant increase in General Health Questionnaire scores. These findings suggest that rs793391 may be linked to both COPD progression and ICS response and could contribute to more personalized treatment strategies in COPD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructivePolymorphism, Single NucleotideAdrenal Cortex HormonesHumansMaleFemaleAdministration, InhalationMiddle AgedAgedTreatment OutcomeBudesonide

Stichwörter der Autor:innen

COPD pharmacogeneticsinhaled corticosteroidspersonalized therapyprecision medicinesingle nucleotide polymorphismsulfatase modifying factor 1sulfatases

Substanzen

Adrenal Cortex HormonesBudesonide

Autor:innen und Institutionen

  • Clinic of Respiratory Medicine, University of Freiburg, Faculty of Medicine, University of Freiburg, 79098 Freiburg im Breisgau, Germany.
  • First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Emergency Department, University Hospital Basel, 4031 Basel, Switzerland.
  • Pulmonary Department, Hippokration General Hospital of Thessaloniki, 54642 Thessaloniki, Greece.
  • Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
  • Clinical Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.

ORCID-Profile: Charikleia Ntenti, Maria Pascarella, Björn C Frye, Sebastian Fähndrich

Förderung

  • Swiss National Foundation
  • AstraZeneca
  • Clinic of Pneumology, University Hospital Basel, Switzerland
  • Astra Zeneca

Zitieren

APA

Ntenti, C., Papakonstantinou, E., Grize, L., Pascarella, M., Frye, B. C., Fähndrich, S., Ioannidou, D., Savic Prince, S., Goulas, A., & Stolz, D. (2025). SUMF1 Common Variant rs793391 Is Associated with Response to Inhaled Corticosteroids in Patients with COPD. International Journal of Molecular Sciences, 26(20), 10225. https://doi.org/10.3390/ijms262010225

Vancouver

Ntenti C, Papakonstantinou E, Grize L, Pascarella M, Frye BC, Fähndrich S, et al. SUMF1 Common Variant rs793391 Is Associated with Response to Inhaled Corticosteroids in Patients with COPD. International Journal of Molecular Sciences. 2025;26(20):10225. doi:10.3390/ijms262010225

BibTeX
@article{Ntenti2025,
  author = {Ntenti, Charikleia and Papakonstantinou, Eleni and Grize, Leticia and Pascarella, Maria and Frye, Björn C and Fähndrich, Sebastian and Ioannidou, Despoina and Savic Prince, Spasenija and Goulas, Antonis and Stolz, Daiana},
  title = {SUMF1 Common Variant rs793391 Is Associated with Response to Inhaled Corticosteroids in Patients with COPD},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {20},
  pages = {10225},
  doi = {10.3390/ijms262010225}
}
Kostenlos starten →